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redictors of Mortality in Patients With
eart Failure and Preserved Systolic
unction in the Digitalis Investigation Group Trial
. Christopher Jones, MD, Gary S. Francis, MD, FACC, Michael S. Lauer, MD, FACC
leveland, Ohio
OBJECTIVES We identified predictors of mortality in patients with preserved ejection fraction (EF) and
clinical heart failure (HF).
BACKGROUND Although diastolic HF is common, the factors that predict mortality have not been clearly
defined.
METHODS We studied 988 patients with HF and preserved EF enrolled in the Digitalis Investigation
Group (DIG) trial. Survival analyses were employed to identify variables associated with
mortality.
RESULTS During 3.1 years of follow-up, 231 (23%) patients died. Among 18 variables considered, the
strongest independent predictors of death were glomerular filtration rate (adjusted hazard
ratio for one standard deviation decrease 1.50, 95% confidence interval [CI] 1.35 to 1.67, p
 0.0001), New York Heart Association functional class III or IV (adjusted hazard ratio 1.64,
95% CI 1.20 to 2.18, p  0.0011), male gender (adjusted hazard ratio 1.71, 95% CI 1.26 to
2.32, p  0.0005), and older age (adjusted hazard ratio for one standard deviation increase of
age2 1.28, 95% CI 1.08 to 1.50, p  0.0019). A risk score was developed to estimate
long-term mortality.
CONCLUSIONS Diastolic HF is associated with a high death rate. Important predictors of death include
impaired renal function, worse functional class, male gender, and older age. (J Am Coll
Cardiol 2004;44:1025–9) © 2004 by the American College of Cardiology Foundationfi
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whe Digitalis Investigation Group (DIG) enrolled 6,800
atients between 1991 and 1993 with clinical heart failure
HF) and depressed ejection fraction (EF) in a randomized,
ouble-blind, placebo-controlled trial of digoxin therapy
1). Upon the advice of the late Dr. Richard Gorlin, an
ncillary study was concomitantly conducted consisting of
88 patients with clinical HF and EF more than 0.45.
hile the overall mortality in this group (23%) was lower
han that in the main trial (35%), the absolute mortality was
till substantial. Although it was determined that digoxin
herapy was not associated with altered mortality in either
opulation, other predictors of mortality for the patients in
he ancillary trial were not reported. Accordingly, we un-
ertook this analysis to better define prognostic indicators in
atients with clinical HF and preserved systolic function.
ETHODS
tudy design. The details of the trial design and rationale
ave been previously published (1). Patients were enrolled
rom 302 North American centers, and were eligible for the
ncillary trial if they had stable HF, EF 0.45, and sinus
hythm. Heart failure was defined by predefined symptoms,
igns, and chest radiograph criteria. Cardiothoracic (CT)
atio was estimated from a chest radiograph. Glomerular
From the Department of Cardiovascular Medicine, Cleveland Clinic Foundation,
leveland, Ohio.
Manuscript received March 23, 2004; revised manuscript received April 19, 2004,sccepted May 3, 2004.ltration rate (GFR) was estimated from the serum creati-
ine based on the Modification of Diet in Renal Disease
MDRD) equation (2). Informed consent was obtained
rom all patients. The primary outcome used for the
ncillary trial was combined overall mortality and hospital-
zation from worsening HF.
tatistical analysis. Associations of candidate variables
ith mortality were assessed by Kaplan-Meier plots and
og-rank chi-square statistics. All variables were considered
n multivariable Cox regression analyses. Bootstrap resam-
ling with replacement (3) was performed to create 1,000
ew data sets, each with a size equal to the original data set.
resampling analysis with 1,000 iterations was performed
o identify the variables that entered into 50% of the Cox
egression models, with p  0.05 for retention of variables
4). A second series of 1,000 iterations was performed with
nly the variables that were retained in the first iteration.
his second analysis was used to estimate hazard ratios and
onfidence intervals (CI).
Analyses were performed using SAS version 8.2 software
SAS Institute, Cary, North Carolina). Values of p  0.05
ere considered significant.
ESULTS
aseline characteristics. Baseline characteristics of the
88 patients in the ancillary trial are listed in Table 1. There
ere 285 patients (29%) with diabetes, which was veryimilar to the proportion of patients with diabetes among
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Mortality in Diastolic HF September 1, 2004:1025–9atients with systolic dysfunction (1,933 of 6,800 [28%], p
0.78).
ortality. There were 231 total deaths in a mean
ollow-up period of 3.5 0.7 years. Univariate predictors of
ortality included increasing age, decreasing GFR, decreas-
ng body mass index (BMI), worsening functional status,
ncreasing CT ratio, presence of diabetes, use of vasodila-
ors, and use of diuretics (Figs. 1A and 1B). Etiology of HF,
ender, and EF did not predict death (Fig. 1C).
ultivariable Cox regression analyses. The only variables
o enter more than 90% of the bootstrap-generated models
ere GFR and New York Heart Association (NYHA)
unctional class III or IV. Male gender, increasing age, use
f diuretics, decreasing BMI, increasing CT ratio, diabetes,
nd use of vasodilators entered more than 50% of the
odels (Table 2).
Abbreviations and Acronyms
BMI  body mass index
CI  confidence interval
CT  cardiothoracic
DIG  Digitalis Investigation Group
EF  ejection fraction
GFR  glomerular filtration rate
HF  heart failure
MDRD  Modification of Diet in Renal Disease
NYHA  New York Heart Association
able 1. Baseline Characteristics of 988 Patients Enrolled in
IG Ancillary Trial
Characteristics
Number
(Percentage)
atient demographics
Age, yrs (SD) 67 (10)
Men 581 (59)
Caucasian 851 (86)
Diabetes 285 (29)
BMI, kg/m2 (SD) 29 (6)
NYHA functional class III or IV 218 (22)
xam or testing data
EF, % (SD) 55 (8)
SBP, mm Hg (SD) 138 (21)
DBP, mm Hg (SD) 77 (11)
CT ratio (SD) 0.52 (0.08)
GFR, ml/min/m2 (SD) 62 (20)
Potassium level, mmol/l (SD) 3.9 (1.3)
eart failure etiology
Ischemic 557 (56)
Hypertensive 222 (22)
Other 209 (21)
edical treatment
Nitrates 385 (39)
ACE inhibitor 852 (86)
Non–potassium-sparing diuretics 751 (76)
Potassium-sparing diuretics 79 (8)
Vasodilators 243 (25)
CE  angiotensin-converting enzyme; BMI  body mass index; CT  cardiotho-
acic; DBP  diastolic blood pressure; DIG  Digitalis Investigation Group; EF 
jection fraction; GFR  glomerular filtration rate; NYHA  New York Heartrssociation; SBP  systolic blood pressure.isk score. A risk score for mortality was developed using
ach of the 10 variables from the multivariable bootstrap
odel entering more than 50% of the models (Appendix).
Kaplan-Meier curve demonstrating worsening survival
or the high-risk score quartiles is presented in Figure 2.
he fourth quartile of risk score was a high-risk group, with
four-year mortality of nearly 50%.
reatment with digoxin or placebo. There was no asso-
iation between treatment status and mortality, as previously
eported (1). We found no interaction between renal func-
ion and treatment status for prediction of death (p for
nteraction 0.17).
Blood levels for digoxin that were obtained within one
onth of enrollment were available in 289 patients, among
hom 75 died. We found no association between digoxin
evel and mortality risk (hazard ratio for 0.2 mg/dl increase
n digoxin level 1.03, 95% CI 0.96 to 1.10, p  0.49). This
ack of association persisted even after adjusting for renal
unction (adjusted hazard ratio 0.99, 95% CI 0.92 to 1.07,
 0.81).
ISCUSSION
he DIG ancillary study enrolled 988 patients with clinical
F and preserved systolic function, thus representing one of
he largest such prospectively gathered populations assem-
led to date. A unique feature of this cohort is that it was
argely derived from an ambulatory population. While the
rimary outcome in the original ancillary trial was the
ombined end points of death or hospitalization from HF,
he investigators demonstrated that digoxin was not associ-
ted with any difference in mortality in the ancillary trial (1).
e have shown that important predictors of mortality in
hese patients with clinical HF and preserved systolic
unction include worsening renal function, NYHA func-
ional class III or IV, and male gender.
The findings that poor functional class, worsening renal
unction, and male gender are associated with an adverse
ffect in a general HF patient population are not novel (5–9).
ur group recently published a post-hoc analysis of the
IG trial exercise substudy demonstrating increasing mor-
ality with decreasing quartile of creatinine clearance and
-min walk distance 262 m (10). Similarly, a post-hoc
nalysis of the Studies Of Left Ventricular Dysfunction
SOLVD) registry demonstrated worse combined outcome
f hospitalization or death for the subset of patients with
reatinine clearance60 ml/min (11). Explanations for why
enal insufficiency may worsen prognosis in patients with
iastolic HF are provisional. Two groups, however, found
mprovement in echocardiographic measures of diastolic
unction in end-stage renal disease patients undergoing
emodialysis (12,13). One hypothesis for the improvement
as attributed to a possible decrease in interstitial edema.
The risk score has several potential uses. With current
and-held computer capability, a patient’s risk score may be
eadily determined during the initial encounter. This score
F
U
p
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September 1, 2004:1025–9 Mortality in Diastolic HFigure 1. (A) Univariable predictors of mortality. Age, glomerular filtration rate (GFR), and body mass index (BMI) are presented in quartiles. (B)
nivariable predictors of mortality. Cardiothoracic (CT) ratio is presented in quartiles. (C) Univariable predictors of mortality. Ejection fraction (EF) is
resented in quartiles. HTN  hypertension; NYHA  New York Heart Association.
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Mortality in Diastolic HF September 1, 2004:1025–9ay then be used to estimate prognosis, thus potentially
acilitating discussions between clinician and patient regard-
ng therapies and lifestyle changes. We also foresee our risk
core being used to identify higher risk populations for entry
nto clinical trials of therapeutics. Two large, randomized,
ontrolled trials have now been performed attempting to
dentify appropriate therapy for patients with clinical HF
nd preserved EF without significant success (1,14). Our
able 2. Potential Variables Associated With Mortality in
ootstrap Models, Presented in Descending Order of Strength;
,000 Bootstrap Models Performed in Each Iteration
Variables
Bootstrap
Models Entered
(%)
Hazard
Ratio 95% CI
FR* 1,000 (100) 1.50 1.35–1.67
YHA functional
class III/IV
917 (92) 1.64 1.20–2.18
ale gender 885 (89) 1.71 1.26–2.32
ge† 838 (84) 1.28 1.08–1.50
iuretics 788 (79) 1.83 1.26–2.82
MI‡ 703 (70) 1.22 1.06–1.39
T ratio§ 656 (66) 1.19 1.05–1.36
iabetes 595 (60) 1.45 1.06–1.95
asodilators 585 (59) 1.42 1.03–1.89
-sparing diuretics 583 (58) 1.75 1.01–2.73
BP 287 (29) — —
CE inhibitors 136 (14) — —
aucasian 131 (13) — —
otassium level 111 (11) — —
BP 90 (9) — —
itrates 87 (9) — —
schemic etiology 73 (7) — —
F 69 (7) — —
After inverse transformation (1/GFR); †after quadratic transformation (Age/65)2;
after inverse transformation (1/BMI); §after quadratic transformation (CT ratio)2;
after logarithmic transformation (Log [DBP]/65).
CI  confidence interval; Diuretics  use of nonpotassium-sparing diuretics;
-sparing diuretics  potassium sparing diuretics; other abbreviations as in Table 1.Figure 2. Kaplan-Meier survival curvesisk score would allow for sicker patients to be identified a
riori, thus promoting the entry of patients with larger
xpected event rates.
Several limitations are worthy of mention. Although the
IG trial data set is well validated, it is aging. Records
egarding beta-blocker therapy were not collected, as beta-
lockade was not considered to be part of the therapeutic
rmamentarium for congestive HF at the time of the study
esign and enrollment. Similarly, no information specifi-
ally regarding aldosterone antagonists or angiotensin-
eceptor blockers was collected. Echocardiography was not
erformed as a systematic component in the DIG trial; this
s an important acknowledged limitation. It is indeed quite
ikely that future work in other cohorts may demonstrate
hat certain echocardiographic measures, like left atrial size,
eft ventricular mass, or left ventricular wall thickness, may
ell emerge as important prognostic markers in diastolic
F. The same applies to other newer measures, including
eurohormonal perturbations. We cannot contend that our
atients had diastolic dysfunction as we do not have
chocardiographic parameters indicating abnormal filling
atterns (15–18). The estimation of renal function was not
erformed by the more commonly used Cockcroft-Gault
quation as we had only BMI, and not weight, information
19). Nevertheless, some argue that the MDRD equation
ay be more accurate (20). We did not have data on the
xtent or severity of coronary disease, which may well have
rognostic importance. Lastly, the risk score needs valida-
ion in a separate cohort.
onclusions. Renal insufficiency and poor exercise capac-
ty add substantially to the annualized mortality in patients
ith HF and preserved EF, as they do for patients with HF
nd impaired systolic function. In planning future clinical
rials, which are desperately needed for patients with HFfor the quartiles of the risk score.
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September 1, 2004:1025–9 Mortality in Diastolic HFnd preserved EF (21), one might be able to enrich the
opulation by incorporating such entry criteria, thus ensur-
ng that primary end points will be met with a smaller
ample size than what otherwise might be deemed
ecessary.
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PPENDIX
Risk score 10 [(1 ⁄ {GFR ⁄ 60} 0.94250)
 (NYHA functional class III/IV 0.49544)
 (female gender0.53467) ({age ⁄ 65}2 0.77739)
 (diuretics 0.60422) (1 ⁄ {BMI ⁄ 30} 0.88877)
 ({CT ratio}2 2.13163) (diabetes 0.37152)
 (vasodilators 0.34986)
 (K-sparing diuretics 0.55798)]
here, NYHA functional class III/IV  1, if NYHA
unctional class III/IV is present, female gender  1, if
emale gender is present, diuretics  1, if diuretics are used,
iabetes  1, if diabetes is present, vasodilators  1, if
asodilators are used, and K-sparing diuretics  1, if
otassium-sparing diuretics are used.
